This study is in progress, not accepting new patients
Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at Santa Monica, California and other locations
- Dates
- study startedcompletion around
- Principal Investigator
- by Richard Finn
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at UCLA
- Richard Finn
HS Clinical Professor, Medicine. Authored (or co-authored) 243 research publications
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Merck Sharp & Dohme LLC
- Links
- Merck Clinical Trials Information
- ID
- NCT03713593
- Phase
- Phase 3 research study
- Study Type
- Interventional
- Participants
- About 794 people participating
- Last Updated